HIV-1 integrase, a member of a polynucleotidyl transferases superfamily, catalyzes the insertion of the viral DNA into the genome of host cells[2]. HIV-1 IN acts as a key component of the Retroviral Pre-Integration Complex (PIC)[3].the HIV-1 replication depends not only on distinct steps but also lens epithelium-derived growth factor/p75 (LEDGF/p75)[4]. HIV-1 integrase (IN) inhibitors are primary drugs in Highly active antiretroviral therapy (HAART) regimens targeting integration step in the HIV-1 life cycle[5]. Lavendustin B is an inhibitor of HIV-1 integrase interaction with LEDGF/p75 with an IC50 of 94.07 μM. Lavendustin B is an ATP-competitive GLUT1 inhibitor with a Ki of 15 µM. Lavendustin B is also a weak inhibitor of tyrosine kinases[6]. In HL-60 cells, Lavendustin B (0-1000 µM) inhibits the uptake of methylglucose, deoxyglucose, and dehydroascorbic acid in human erythrocytes in a dose-dependent manner, with 50% inhibition observed at approximately 10-30 µM. Moreover, increasing concentrations of Lavendustin B inhibited, in a dose-dependent manner, the binding of cytochalasin B to human erythrocyte membranes[7].
搜索
